CytoMed Therapeutics Limited
Explore CytoMed Therapeutics Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Regeneron Pharmaceuticals, Inc. | $635.45 | 15.1 | $66.78 B | 0.6% | 10.23% | 14.32% | $821.11 / $476.49 | $295.71 |
| 2. | Alnylam Pharmaceuticals, Inc. | $303.05 | 70.37 | $40.62 B | — | 14.33% | 98.29% | $495.55 / $283.1 | $5.96 |
| 3. | Royalty Pharma plc | $55.87 | 38.89 | $32.17 B | 1.71% | 8.21% | 12.67% | $56.07 / $33.37 | $11.22 |
| 4. | Revolution Medicines, Inc. | $149.23 | — | $31.73 B | — | -57.28% | -54.06% | $166.5 / $34 | $8.28 |
| 5. | Roivant Sciences Ltd. | $28.58 | — | $27.48 B | — | -21.06% | -6.85% | $32.79 / $10.71 | $6.28 |
| 6. | Insmed Incorporated | $94.22 | — | $21.48 B | — | -55.4% | -130.11% | $212.75 / $70.57 | $3.45 |
| 7. | Incyte Corporation | $102.38 | 14.53 | $20.8 B | — | 24.67% | 29.2% | $112.29 / $66.74 | $26.04 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.32 M | 0.07 M | 0 M | 0 M |
| Operating Profit | -4.24 M | -3.13 M | -3.84 M | -1.86 M |
| Net Profit | -3.98 M | -2.52 M | -4.13 M | -3.13 M |
| EPS in Rs | -0.34 | -0.21 | -0.35 | -0.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.98 M | 10.07 M | 12.37 M | 5.23 M |
| Total Liabilities | 1.13 M | 1.02 M | 1.12 M | 4.64 M |
| Equity | 6.54 M | 8.97 M | 11.25 M | 0.59 M |
| Current Assets | 3.66 M | 6 M | 10.1 M | 2.49 M |
| Current Liabilities | 0.71 M | 0.61 M | 0.72 M | 4.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.7 M | -2.71 M | -3.53 M | -1.4 M |
| Investing CF | 0.93 M | 1.13 M | -2.73 M | -0.47 M |
| Financing CF | 0.21 M | -0.06 M | 10.92 M | 0.97 M |
| Free CF | -4.4 M | -4.2 M | -3.59 M | -1.87 M |
| Capex | -0.7 M | -1.49 M | -0.06 M | -0.47 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 39.11% | -31.99% | — | — |
| Profit Margin % | -3621.1% | — | — | — |
| Operating Margin % | -4504.29% | — | — | — |
| Gross Margin % | 75.37% | — | — | — |
| EBITDA Margin % | -3116.77% | — | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.
Frequently Asked Questions — CytoMed Therapeutics Limited
Will CytoMed Therapeutics Limited stock hit $2 in 2026?
CytoMed Therapeutics Limited (GDTC) is currently trading at $1.29, with a 52-week range of $0.68 to $3.68. Reaching the $2 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Whether CytoMed Therapeutics Limited can reach $2 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the GDTC Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is CytoMed Therapeutics Limited stock worth buying at $1.29?
Whether CytoMed Therapeutics Limited (GDTC) is worth buying at $1.29 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency: CytoMed Therapeutics Limited has a Return on Capital Employed (ROCE) of -33.1%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -58.1%.
Financial health: The Debt-to-Equity ratio of 7.04 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.
Analyst view: Analyst estimates are not currently available for GDTC. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for CytoMed Therapeutics Limited (GDTC) in 2026?
Analyst price target data for CytoMed Therapeutics Limited (GDTC) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore GDTC's financial ratios, historical returns, and fundamental data available on this page to form your own view.
What will CytoMed Therapeutics Limited stock be worth in 2029?
Projecting CytoMed Therapeutics Limited (GDTC)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.
In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.
You can model different scenarios — conservative, base, and bull case — using the GDTC Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.